Sign In
Buy MORF
$56.99
+0 (+0%)
At Close: Nov 14, 2024
New Strong Buy Stocks for February 14th
06:50am, Wednesday, 14'th Feb 2024
GLTO, LUMN, MORF, SFST and STOK have been added to the Zacks Rank #1 (Strong Buy) List on February 14, 2023.
Wall Street Analysts Think Morphic Holding, Inc. (MORF) Could Surge 57.22%: Read This Before Placing a Bet
10:55am, Thursday, 08'th Feb 2024
The consensus price target hints at a 57.2% upside potential for Morphic Holding, Inc. (MORF). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earn
Wall Street Analysts Believe Morphic Holding, Inc. (MORF) Could Rally 110.28%: Here's is How to Trade
11:18am, Friday, 05'th Jan 2024
The mean of analysts' price targets for Morphic Holding, Inc. (MORF) points to an 110.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreemen
Morphic to Present at the 42nd Annual J.P. Morgan Healthcare Conference
04:05pm, Wednesday, 03'rd Jan 2024
-Dr. Praveen Tipirneni, returns in full capacity as Chief Executive Officer from medical leave- WALTHAM, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology c
Does Morphic Holding, Inc. (MORF) Have the Potential to Rally 92.88% as Wall Street Analysts Expect?
11:16am, Wednesday, 20'th Dec 2023
The average of price targets set by Wall Street analysts indicates a potential upside of 92.9% in Morphic Holding, Inc. (MORF). While the effectiveness of this highly sought-after metric is questionab
Wall Street Analysts See a 150.17% Upside in Morphic Holding, Inc. (MORF): Can the Stock Really Move This High?
11:18am, Friday, 01'st Dec 2023
The mean of analysts' price targets for Morphic Holding, Inc. (MORF) points to a 150.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement
Morphic Holding, Inc. (MORF) Moves to Buy: Rationale Behind the Upgrade
01:33pm, Thursday, 09'th Nov 2023
Morphic Holding, Inc. (MORF) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Morphic Therapeutic to Host Webcast to Present EMERALD-1 Full Data Set
08:00am, Monday, 09'th Oct 2023
WALTHAM, Mass., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious ch
Morphic Holding: The Price Drop Is Very Interesting
05:02pm, Thursday, 28'th Sep 2023
Morphic Holding, Inc.'s stock has dropped 61% in just 2 months, calling into question its $3bn valuation. The company's lead asset, MORF-057, targets the integrin α4β7, but faces tough competition f
-Orally administered MORF-057 achieved primary endpoint and demonstrates clinically meaningful improvements across secondary and exploratory measures-
Morphic Holding, Inc. (MORF) Reports Q2 Loss, Lags Revenue Estimates
10:31am, Thursday, 03'rd Aug 2023
Morphic Holding, Inc. (MORF) came out with a quarterly loss of $0.92 per share versus the Zacks Consensus Estimate of a loss of $0.90. This compares to earnings of $0.68 per share a year ago.
Morphic: High Valuation Not Justified By Data, Development Status, Or Cash
03:12pm, Monday, 10'th Jul 2023
Morphic Holding, Inc. is progressing with its trials nicely enough. I just have a problem with the nearly $3bn valuation for this phase 2 stage company. Nothing they have done or said justifies it.
3 Stocks That Could Skyrocket by This Time Next Summer
03:22pm, Thursday, 08'th Jun 2023
I'm searching for the best stocks to skyrocket by this time next summer. A quick screen of U.S.-listed stocks tells me there are 51 that doubled or better over the past year out of 1,904 companies wit
Morphic to Present at the Jefferies Global Healthcare Conference
04:05pm, Tuesday, 06'th Jun 2023
WALTHAM, Mass., June 06, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious ch
Morphic to Present at 2023 RBC Capital Markets Global Healthcare Conference
08:30am, Friday, 12'th May 2023
WALTHAM, Mass., May 12, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chr
